{"pmid":32267556,"title":"COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.","text":["COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.","We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.(1-3) However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited.","Pharmacotherapy","Lodise, Thomas P","Rybak, Michael J","32267556"],"abstract":["We are living in unprecedented times. While we had near pandemic events in the recent past with SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), we have never experienced anything like coronavirus (COVID-19), also known as SARS-CoV-2 infection, since the Spanish flu. In contrast to the Spanish flu where medical care was limited, we are equipped to combat COVID-19 but there is considerable work ahead with many uncertainties. At this critical time, we must come together as one united country and world to stop the spread and provide the best care possible for individuals who contract the virus and develop infection. A number of novel and repurposed therapies agents with activity against SARS-CoV-2 have been identified and most institutions have developed clinical pathways to operationalize their use in appropriate COVID-19 patients.(1-3) However, optimal drug therapy decisions for those with moderate to severe COVID-19 infections are extremely challenging at this time as evidence is limited."],"journal":"Pharmacotherapy","authors":["Lodise, Thomas P","Rybak, Michael J"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267556","week":"202015|Apr 06 - Apr 12","doi":"10.1002/phar.2396","source":"PubMed","locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment"],"weight":1,"_version_":1663609715728318464,"score":7.9164424,"similar":[{"pmid":32143990,"title":"The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.","text":["The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.","The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002-2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.","J Autoimmun","Yang, Yongshi","Peng, Fujun","Wang, Runsheng","Guan, Kai","Jiang, Taijiao","Xu, Guogang","Sun, Jinlyu","Chang, Christopher","32143990"],"abstract":["The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002-2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world."],"journal":"J Autoimmun","authors":["Yang, Yongshi","Peng, Fujun","Wang, Runsheng","Guan, Kai","Jiang, Taijiao","Xu, Guogang","Sun, Jinlyu","Chang, Christopher"],"date":"2020-03-08T11:00:00Z","year":2020,"_id":"32143990","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.jaut.2020.102434","keywords":["Bats","Coronavirus","Epidemic","Epidemiology","Flu","Human to human transmission","Pandemic","Pneumonia","Pyroptosis","SARS-CoV","SARS-CoV-2"],"source":"PubMed","locations":["Spanish","Wuhan","China","Hubei","Asians","Huanan"],"countries":["Spain","China"],"countries_codes":["ESP|Spain","CHN|China"],"topics":["Diagnosis","Transmission","Prevention","Mechanism"],"weight":1,"_version_":1663352134174769153,"score":209.99867},{"pmid":32259313,"title":"Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","text":["Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.","Pharmacotherapy","Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S","32259313"],"abstract":["The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic."],"journal":"Pharmacotherapy","authors":["Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259313","week":"202015|Apr 06 - Apr 12","doi":"10.1002/phar.2398","keywords":["Antivirals","Critical care","Cytochrome P450","Dialysis","Infectious disease","Liver","Pharmacokinetics","Pharmacology","Renal"],"source":"PubMed","locations":["vivo"],"topics":["Treatment"],"weight":1,"_version_":1663450393445662720,"score":205.0501},{"pmid":32273245,"title":"The COVID-19 pandemic: Important considerations for contact lens practitioners.","text":["The COVID-19 pandemic: Important considerations for contact lens practitioners.","A novel coronavirus (CoV), the Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), results in the coronavirus disease 2019 (COVID-19). As information concerning the COVID-19 disease continues to evolve, patients look to their eye care practitioners for accurate eye health guidance. There is currently no evidence to suggest an increased risk of contracting COVID-19 through contact lens (CL) wear compared to spectacle lens wear and no scientific evidence that wearing standard prescription spectacles provides protection against COVID-19 or other viral transmissions. During the pandemic there will potentially be significant changes in access to local eyecare. Thus, it is imperative CL wearers are reminded of the steps they should follow to minimise their risk of complications, to reduce their need to leave isolation and seek care. Management of adverse events should be retained within optometric systems if possible, to minimise the impact on the wider healthcare service, which will be stretched. Optimal CL care behaviours should be the same as those under normal circumstances, which include appropriate hand washing (thoroughly with soap and water) and drying (with paper towels) before both CL application and removal. Daily CL cleaning and correct case care for reusable CL should be followed according to appropriate guidelines, and CL exposure to water must be avoided. Where the availability of local clinical care is restricted, practitioners should consider advising patients to reduce or eliminate sleeping in their CL (where patients have the appropriate knowledge about correct daily care and access to suitable lens-care products) or consider the option of moving patients to daily disposable lenses (where patients have appropriate lens supplies available). Patients should also avoid touching their face, including their eyes, nose and mouth, with unwashed hands and avoid CL wear altogether if unwell (particularly with any cold or flu-like symptoms).","Cont Lens Anterior Eye","Jones, Lyndon","Walsh, Karen","Willcox, Mark","Morgan, Philip","Nichols, Jason","32273245"],"abstract":["A novel coronavirus (CoV), the Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), results in the coronavirus disease 2019 (COVID-19). As information concerning the COVID-19 disease continues to evolve, patients look to their eye care practitioners for accurate eye health guidance. There is currently no evidence to suggest an increased risk of contracting COVID-19 through contact lens (CL) wear compared to spectacle lens wear and no scientific evidence that wearing standard prescription spectacles provides protection against COVID-19 or other viral transmissions. During the pandemic there will potentially be significant changes in access to local eyecare. Thus, it is imperative CL wearers are reminded of the steps they should follow to minimise their risk of complications, to reduce their need to leave isolation and seek care. Management of adverse events should be retained within optometric systems if possible, to minimise the impact on the wider healthcare service, which will be stretched. Optimal CL care behaviours should be the same as those under normal circumstances, which include appropriate hand washing (thoroughly with soap and water) and drying (with paper towels) before both CL application and removal. Daily CL cleaning and correct case care for reusable CL should be followed according to appropriate guidelines, and CL exposure to water must be avoided. Where the availability of local clinical care is restricted, practitioners should consider advising patients to reduce or eliminate sleeping in their CL (where patients have the appropriate knowledge about correct daily care and access to suitable lens-care products) or consider the option of moving patients to daily disposable lenses (where patients have appropriate lens supplies available). Patients should also avoid touching their face, including their eyes, nose and mouth, with unwashed hands and avoid CL wear altogether if unwell (particularly with any cold or flu-like symptoms)."],"journal":"Cont Lens Anterior Eye","authors":["Jones, Lyndon","Walsh, Karen","Willcox, Mark","Morgan, Philip","Nichols, Jason"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32273245","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.clae.2020.03.012","keywords":["COVID-19","Contact lens","Lens care","Lens wear"],"source":"PubMed","topics":["Prevention"],"weight":1,"e_drugs":["Water"],"_version_":1663712077899890689,"score":192.90222},{"pmid":32243259,"title":"The COVID-19 pandemic and research shutdown: staying safe and productive.","text":["The COVID-19 pandemic and research shutdown: staying safe and productive.","The Coronavirus Disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, has caused severe disease outcomes and widespread infections not seen in terms of its case fatality rate and global economic impact since the 1918-1919 Spanish flu; the latter leading to 675,000 deaths in the United States (US) (50 million worldwide).","J Clin Invest","Omary, M Bishr","Eswaraka, Jeetendra R","Kimball, S David","Moghe, Prabhas V","Panettieri, Reynold A Jr","Scotto, Kathleen W","32243259"],"abstract":["The Coronavirus Disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, has caused severe disease outcomes and widespread infections not seen in terms of its case fatality rate and global economic impact since the 1918-1919 Spanish flu; the latter leading to 675,000 deaths in the United States (US) (50 million worldwide)."],"journal":"J Clin Invest","authors":["Omary, M Bishr","Eswaraka, Jeetendra R","Kimball, S David","Moghe, Prabhas V","Panettieri, Reynold A Jr","Scotto, Kathleen W"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243259","week":"202014|Mar 30 - Apr 05","doi":"10.1172/JCI138646","source":"PubMed","locations":["United States","US","Spanish"],"countries":["Spain","United States"],"countries_codes":["ESP|Spain","USA|United States"],"weight":0,"_version_":1663352135709884417,"score":190.45729},{"pmid":32226290,"pmcid":"PMC7098027","title":"Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.","text":["Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19.","Coronaviruses (CoVs) are a group of enveloped, single-stranded positive genomic RNA viruses and some of them are known to cause severe respiratory diseases in human, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the ongoing coronavirus disease-19 (COVID-19). One key element in viral infection is the process of viral entry into the host cells. In the last two decades, there is increasing understanding on the importance of the endocytic pathway and the autophagy process in viral entry and replication. As a result, the endocytic pathway including endosome and lysosome has become important targets for development of therapeutic strategies in combating diseases caused by CoVs. In this mini-review, we will focus on the importance of the endocytic pathway as well as the autophagy process in viral infection of several pathogenic CoVs inclusive of SARS-CoV, MERS-CoV and the new CoV named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and discuss the development of therapeutic agents by targeting these processes. Such knowledge will provide important clues for control of the ongoing epidemic of SARS-CoV-2 infection and treatment of COVID-19.","Int J Biol Sci","Yang, Naidi","Shen, Han-Ming","32226290"],"abstract":["Coronaviruses (CoVs) are a group of enveloped, single-stranded positive genomic RNA viruses and some of them are known to cause severe respiratory diseases in human, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the ongoing coronavirus disease-19 (COVID-19). One key element in viral infection is the process of viral entry into the host cells. In the last two decades, there is increasing understanding on the importance of the endocytic pathway and the autophagy process in viral entry and replication. As a result, the endocytic pathway including endosome and lysosome has become important targets for development of therapeutic strategies in combating diseases caused by CoVs. In this mini-review, we will focus on the importance of the endocytic pathway as well as the autophagy process in viral infection of several pathogenic CoVs inclusive of SARS-CoV, MERS-CoV and the new CoV named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and discuss the development of therapeutic agents by targeting these processes. Such knowledge will provide important clues for control of the ongoing epidemic of SARS-CoV-2 infection and treatment of COVID-19."],"journal":"Int J Biol Sci","authors":["Yang, Naidi","Shen, Han-Ming"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32226290","week":"202014|Mar 30 - Apr 05","doi":"10.7150/ijbs.45498","keywords":["*COVID-19","*Coronaviruses","*SARS-CoV-2","*autophagy","*endocytic pathway"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135249559552,"score":188.66808}]}